MarginsXMarginsX
Home › Markets › Health Care › HKPD

Cellyan Biotechnology Co. Ltd (HKPD)

HKPD trades on Nasdaq in Health Care, Other Pharmaceuticals. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.61
-0.62% on the day
Market cap
$4.0M
Nano cap
Revenue · 2025
$13.4M
-33.9% on 2024
Net income · 2025
-$1.1M
-8.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/2007702/000121390026086725/0001213900-26-086725-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2026-03-31.

Profile

FieldValue
TickerHKPD on Nasdaq
SectorHealth Care
IndustryOther Pharmaceuticals
CountryHong Kong
IPO year2025
SEC CIK0002007702
SEC industry codeWholesale-Drugs, Proprietaries & Druggists' Sundries
Incorporated inCayman Islands

Financials · 2025

LineValue
Revenue$13.4M
Net income-$1.1M
Operating income-$2.4M
Net margin-8.5%
Operating margin-17.8%
Revenue growth-33.9%
Cash$222K
Total assets$12.8M
P/E (computed)Net income was not positive
P/S (computed)0.3×

Warning signs

Cash runway
3.5 months
$222K cash at March 31, 2026
Share count, 1 year
+48.6%
2025-03-31 to 2026-03-31
Going-concern doubt
No
20-F filed August 7, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-08-07
Cash and burn$222K cash; operating cash flow -$188K a quarter.Report 2026-03-31
Shares outstandingNo cover-page share count in XBRLCover page 2026-03-31
Reverse splits, 3 years1; latest 1-for-20 on 2026-10-26Source 2026-10-26
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-06-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorONESTOP ASSURANCE PAC, Singapore, SingaporePCAOB Form AP 2026-08-10
Late filings, 12 months1 NT noticeNT 20-F 2026-07-31
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-03-31
$13.4M-$1.1M-$752K$222K$878K$13.4M20-F 2026-08-07
FY 2025
2025-03-31
$20.3M-$27K$569K$749K$1.9M$20.3M20-F 2025-08-14
FY 2024
2024-03-31
$16.7M$1.3M-$394K$620K$1.3M$16.7M20-F 2025-08-14
FY 2023
2023-03-31
$12.6M$998K$1.7MNot filedNo debt tags$12.6M20-F 2025-08-14

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
REGISTRATION STATEMENT
F-32026-06-12
Latest annual report
ANNUAL REPORT
20-F2026-08-07
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-11-16

Source: SEC EDGAR submissions feed, 69 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+11.7%
1 month-22.9%
3 months-80.7%
Year to date-90.2%
1 year-93.1%
From 52-week high-93.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Other Pharmaceuticals

TickerCompanyPriceDayMarket cap
MEDSDataMeds AI Inc.$0.6421-13.68%$3.1M
ESYNEnerSyn Global Inc.$1.250.00%$37.2M
ZSTKZeroStack Corp.$2.80-1.75%$61.1M
NUSNu Skin Enterprises Inc.$3.93-2.48%$191.3M
COSMCosmos Health Inc.$2.49-23.15%$250.6M
HLFHerbalife Ltd. Common Shares$16.15+1.19%$1.7B
CAHCardinal Health Inc.$283.85+0.98%$65.6B
CORCencora Inc.$356.94-0.58%$68.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier